IP Library › Granted Patent US 12,102,623
Granted Patent B2
US 12,102,623 · App. 17/932,982 · Granted Oct 1, 2024

Compositions for the treatment of hypertension

Inventors: Anthony Rodgers (Newtown, AU); Stephen MacMahon (Newtown, AU)
Assignee: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
A61K31/4422A61K31/277A61K31/382A61K31/40A61K31/4035A61K31/404A61K31/41A61K31/4178A61K31/4184A61K31/4418A61K31/495A61K31/517A61K31/549A61K31/554A61P9/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,102,623
App. No.
17/932,982
Filed
Sep 16, 2022
Granted
Oct 1, 2024
Kind
B2
Art Unit
1627
USPC
514/356
Abstract

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Claims (16)

1. A pharmaceutical composition for use in the treatment of hypertension comprising:

a. telmisartan in an amount from about 8 mg to about 20 mg;

b. chlorthalidone in an amount from about 10 mg to about 37.5 mg; and

c. amlodipine besylate in an amount from about 1 mg to about 3.75 mg,

wherein the pharmaceutical composition is free of a beta-blocker.

2. The pharmaceutical composition of claim 1 , wherein telmisartan is in an amount from about 8 mg to about 16 mg, chlorthalidone is in an amount from about 10 mg to about 20 mg, and amlodipine besylate is in an amount from about 1 mg to about 2 mg.

3. The pharmaceutical composition of claim 2 , wherein telmisartan is in an amount from about 8 mg to about 12 mg, chlorthalidone is in an amount from about 10 mg to about 15 mg, and amlodipine besylate is in an amount from about 1 mg to about 1.5 mg.

4. The pharmaceutical composition of claim 3 , where telmisartan is in an amount of about 10 mg, chlorthalidone is in an amount of about 12.5 mg, and amlodipine besylate is in an amount of about 1.25 mg.

5. The pharmaceutical composition of claim 2 , wherein telmisartan is in an amount from about 12 mg to about 16 mg, chlorthalidone is in an amount from about 15 mg to about 20 mg, and amlodipine besylate is in an amount from about 1.5 mg to about 2 mg.

6. The pharmaceutical composition of claim 5 , wherein telmisartan is in an amount of about 13.2 mg, chlorthalidone is in an amount of about 16.5 mg, and amlodipine besylate is in an amount of about 1.65 mg.

7. The pharmaceutical composition of claim 1 , wherein telmisartan is in an amount from about 16 mg to about 20 mg, chlorthalidone is in an amount from about 20 mg to about 37.5 mg, and amlodipine besylate is in an amount from about 2 mg to about 3.75 mg.

8. The pharmaceutical composition of claim 7 , wherein telmisartan is in an amount from about 16 mg to about 20 mg, chlorthalidone is in an amount from about 20 mg to about 30 mg, and amlodipine besylate is in an amount from about 2 mg to about 3 mg.

9. The pharmaceutical composition of claim 8 , wherein telmisartan is in an amount of about 20 mg, chlorthalidone is in an amount of about 25 mg, and amlodipine besylate is in an amount of about 2.5 mg.

10. A method of treating hypertension comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.

11. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is suitable for oral administration.

12. The pharmaceutical composition of claim 11 , wherein said pharmaceutical composition is in the form of a pill, tablet, or capsule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2023
From: RODGERS, ANTHONY; MACMAHON, STEPHEN
To: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
Reel/Frame 063682/0559 →
Continuity (6)
Continuation 17014358 · Sep 8, 2020
Continuation 16393774 · Apr 24, 2019
Continuation 15919923 · Mar 13, 2018
Continuation PCTIB2018000083 · Jan 23, 2018
Provisional Application 62450324 · Jan 25, 2017
Related Publication 20230087834A1 · Mar 23, 2023
Cited By (5)
US 12,285,415 US 12,465,599 US 12,521,380 US 12,661,345 US 12,673,047